Pathology & Oncology Research

, Volume 16, Issue 2, pp 217–222 | Cite as

Impact of Tumor Angiogenesis in Peritoneal Mesothelioma After Radical Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy

  • Terence C. Chua
  • Peng Yao
  • Javed Akther
  • David L. MorrisEmail author


Peritoneal mesothelioma is one of the peritoneal surface malignancies where long-term survival is a reality after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Tumor angiogenesis has been shown to be of prognostic significance on survival in mesothelioma. We investigated the impact of survival of patients with peritoneal mesothelioma following CRS and HIPEC to determine the impact of tumor angiogenesis on survival after this radical surgical treatment. Paraffin sections of 23 patients who were treated with CRS and HIPEC were retrieved for immunohistochemical analysis. The immunostaining was performed using monoclonal mouse anti-human antibodies (VEGF-C and CD31) on an autostainer (Autostainer Plus; Dako, Inc.). The intensity of the stains were quantified using the Image-Pro Plus (IPP) 4.5 (Media Cybernetics, Silver Spring, MD). VEGF expression and microvessel density (MVD) using CD31 staining were studied. The median survival was 94 months with a 3-year survival rate of 51%. There was no impact on patient’s age, sex, peritoneal cancer index, tumor histopathology and survival outcomes between patients with low or high MVD and VEGF expression. After CRS and HIPEC, our results demonstrate that the prognostic significance of tumor angiogenesis is negated, highlighting the potential importance of other co-contributory mechanisms in mesotheliomagenesis and undergoing radial treatment.


Mesothelioma Vascular Endothelial Growth Factor CD 31 Antigen Angiogenesis Cytoreductive surgery 


Conflict of Interest



  1. 1.
    Chua TC, Yan TD, Morris DL (2009) Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg 52(1):59–64PubMedGoogle Scholar
  2. 2.
    Musk AW, de Klerk NH (2004) Epidemiology of malignant mesothelioma in Australia. Lung Cancer 45(Suppl 1):S21–S23CrossRefPubMedGoogle Scholar
  3. 3.
    Edwards JG, Swinson DEB, Jones JL, Muller S, Waller DA, O’Byrne KJ (2003) Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 124(5):1916–1923CrossRefPubMedGoogle Scholar
  4. 4.
    Masood R, Kundra A, Zhu S, Xia G, Scalia P, Smith DL et al (2003) Malignant mesothelioma growth inhibition by agents that target the VEGF and VEGF-C autocrine loops. Int J Cancer 104(5):603–610CrossRefPubMedGoogle Scholar
  5. 5.
    Edwards JG, Cox G, Andi A, Jones JL, Walker RA, Walker DA et al (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. Br J Cancer 85(6):863–868CrossRefPubMedGoogle Scholar
  6. 6.
    Demirag F, Unsal E, Yilmaz A, Caglar A (2005) Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 128(5):3382–3387CrossRefPubMedGoogle Scholar
  7. 7.
    Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H et al (2008) EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax 63(4):345–351CrossRefPubMedGoogle Scholar
  8. 8.
    Strizzi L, Catalano A, Vianale G, Orecchia S, Casalini A, Tassi G et al (2001) Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol 193(4):468–475CrossRefPubMedGoogle Scholar
  9. 9.
    Konig JE, Tolnay E, Wiethege T, Muller KM (1999) Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435(1):8–12CrossRefPubMedGoogle Scholar
  10. 10.
    Ohta Y, Shridhar V, Bright RK, Kalemkerian GP, Du W, Carbone M et al (1999) VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours. Br J Cancer 81(1):54–61CrossRefPubMedGoogle Scholar
  11. 11.
    Ellis LM, Fidler IJ (1996) Angiogenesis and metastasis. Eur J Cancer 32A(14):2451–2460CrossRefPubMedGoogle Scholar
  12. 12.
    Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027CrossRefPubMedGoogle Scholar
  13. 13.
    Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2(8):573–583CrossRefPubMedGoogle Scholar
  14. 14.
    Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S et al (2008) Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 26(10):1698–1704CrossRefPubMedGoogle Scholar
  15. 15.
    van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M et al (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):6881–6889CrossRefPubMedGoogle Scholar
  16. 16.
    Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834CrossRefPubMedGoogle Scholar
  17. 17.
    Zellos L, Richards WG, Capalbo L, Jaklitsch MT, Chirieac LR, Johnson BE et al (2009) A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 137(2):453–458CrossRefPubMedGoogle Scholar
  18. 18.
    Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42PubMedCrossRefGoogle Scholar
  19. 19.
    Jacquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58Google Scholar
  20. 20.
    Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z et al (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 103(27):10397–10402CrossRefPubMedGoogle Scholar
  21. 21.
    Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29(1):2–17CrossRefPubMedGoogle Scholar
  22. 22.
    Ault JG, Cole RW, Jensen CG, Jensen LC, Bachert LA, Rieder CL (1995) Behavior of crocidolite asbestos during mitosis in living vertebrate lung epithelial cells. Cancer Res 55(4):792–798PubMedGoogle Scholar
  23. 23.
    Topov J, Kolev K (1987) Cytology of experimental mesotheliomas induced with crocidolite asbestos. Acta Cytol 31(3):369–373PubMedGoogle Scholar
  24. 24.
    Craighead JE, Akley NJ, Gould LB, Libbus BL (1987) Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol 129(3):448–462PubMedGoogle Scholar
  25. 25.
    Manning CB, Cummins AB, Jung MW, Berlanger I, Timblin CR, Palmer C et al (2002) A mutant epidermal growth factor receptor targeted to lung epithelium inhibits asbestos-induced proliferation and proto-oncogene expression. Cancer Res 62(15):4169–4175PubMedGoogle Scholar
  26. 26.
    Zanella CL, Posada J, Tritton TR, Mossman BT (1996) Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. Cancer Res 56(23):5334–5338PubMedGoogle Scholar
  27. 27.
    Gazdar AF, Carbone M (2003) Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin Lung Cancer 5(3):177–181CrossRefPubMedGoogle Scholar
  28. 28.
    Aoe K, Hiraki A, Tanaka T, Gemba K-I, Taguchi K, Murakami T et al (2006) Expression of vascular endothelial growth factor in malignant mesothelioma. Anticancer Res 26(6C):4833–4836PubMedGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2009

Authors and Affiliations

  • Terence C. Chua
    • 1
  • Peng Yao
    • 1
  • Javed Akther
    • 1
  • David L. Morris
    • 1
    Email author
  1. 1.Department of SurgeryUniversity of New South Wales, St George HospitalKogarah, SydneyAustralia

Personalised recommendations